



四川大冢制药有限公司产品安全性信息更新

Safety Information Update on Sichuan Otsuka Pharmaceutical Products

尊敬的医疗保健专业人员：

Dear Healthcare Professionals:

四川大冢制药有限公司近期完成了以下产品安全性信息更新，并获得国家药品监督管理局批准，即将发布更新后的说明书。

Sichuan Otsuka has been recently granted the regulatory approval by NMPA for the upcoming version of the package insert of the following product, which contains updated safety information:

产品名称/Product Name: 阿立哌唑口服溶液/Aripiprazole Oral Solution

规格/Strength: 150ml:150mg

版本日期/Version Date: 2023年06月26日/26 Jun 2023

如果您有兴趣在上市包装说明书付印之前深入了解安全性信息的变化，请与我司药物警戒（PV）部门联系。

If you are interested in knowing further about these safety information changes prior to the print of the package insert in the sales pack, please contact our PV Department.

电话/TEL: 028-86083256

邮箱/E-MAIL: LOP-PV@cn.otsuka.com

感谢您对四川大冢制药有限公司产品一如既往的关注和支持。

Thank you for your attention and continued support of Sichuan Otsuka products.

四川大冢制药有限公司

Sichuan Otsuka Pharmaceutical Co., Ltd.

2023年7月5日

05 July 2023

免责声明：医疗保健专业人员告知信是为了与医疗从业人员沟通即将出现在大冢产品说明书中的安全性信息变化。它唯一目的是促进科学的、非促销性的交流。

Disclaimer: This Dear HCP Letter is meant for communicating to the medical practitioner about the upcoming safety changes to be appeared in the package insert of Otsuka products concerned. Its sole purpose is to facilitate scientific, non-promotional communication.